DNA Testing Market Report 2026

The dna testing market size has grown rapidly in recent years. It will grow from $20.04 billion in 2025 to $22.4 billion in 2026 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to advances in molecular diagnostics, infectious disease testing demand, cancer screening adoption, laboratory automation growth, genetic research funding.

The dna testing market size is expected to see strong growth in the next few years. It will grow to $32.71 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to precision medicine integration, ai-based genetic interpretation, population screening programs, clinical genomics expansion, regulatory support for molecular diagnostics. Major trends in the forecast period include expansion of dna testing in clinical diagnostics, growing use in prenatal and newborn screening, rising adoption in oncology and pharmacogenomics, integration of automated testing platforms, increased demand for personalized genetic insights.

The rising prevalence of genetic disorders is expected to drive the growth of the DNA testing market in the coming years. Genetic disorders are conditions caused by abnormalities in an individual’s DNA, resulting in physical, developmental, or functional impairments. The increasing incidence of these disorders is fueled by expanded genetic screening, improved diagnostic capabilities, greater public awareness, and the continued occurrence of consanguineous marriages in certain populations. The DNA testing market supports this need by enabling early and accurate diagnosis, prognosis assessment, personalized treatment planning, and informed family-planning decisions based on an individual’s genetic profile. For example, in February 2023, the World Health Organization (WHO) reported that congenital diseases cause an estimated 240,000 newborn deaths globally within the first 28 days of life, and the Centers for Disease Control and Prevention (CDC) noted that approximately 6,000 babies in the United States are born with Down syndrome each year, representing 1 in every 700 births. Therefore, the growing prevalence of genetic disorders is driving the expansion of the DNA testing market.

Companies in the DNA testing market are focusing on developing advanced diagnostic solutions, such as precancer detection DNA tests, to enable earlier diagnosis, timely intervention, and improved patient outcomes in cancer care. Precancer detection DNA tests are molecular assays that identify early genetic or epigenetic changes, such as mutations or methylation patterns, associated with the initial stages of cancer, allowing clinicians to detect disease before symptoms appear. For instance, in November 2023, Lucid Diagnostics Inc., a US-based esophageal cancer prevention diagnostics company, launched EsoGuard 2.0, a next-generation esophageal DNA test offering improved assay performance and lower costs through enhanced molecular techniques and higher DNA yield. Using the EsoCheck Cell Collection Device, the test analyzes esophageal cell DNA through bisulfite conversion, PCR amplification, and next-generation sequencing to detect gene-specific methylation changes linked to esophageal precancer and cancer, providing clinicians with a powerful tool for early detection and prevention.

In January 2023, QIAGEN N.V., a Netherlands-based biotechnology company, acquired Verogen Inc. for $150 million. Through this acquisition, QIAGEN aims to strengthen its leadership in the human identification and forensics market by incorporating Verogen’s next-generation sequencing tools and services to support global criminal and missing-person investigations. Verogen Inc., a US-based forensic genomics company, specializes in DNA testing solutions using next-generation sequencing technologies for human identification and forensic analysis.

Major companies operating in the dna testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers GmbH, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies, Illumina Inc., PerkinElmer Inc., bioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc, Myriad Genetics Inc., BGI Genomics Co. Ltd., Cepheid, NeoGenomics Laboratories Inc, Ancestry.com LLC, 23andMe Holding Co, Ambry Genetics Corporation, MyHeritage Ltd, Biocartis SA, CENTOGENE N.V., Everlywell Inc, Atlas Biomed Group Limited, Veritas Genetics.

North America was the largest region in the DNA testing market in 2025. The regions covered in the dna testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the DNA testing market by increasing costs of imported instruments, reagents, and diagnostic consumables. Diagnostic laboratories in developed regions are most affected, while emerging markets experience slower technology adoption. These tariffs raise testing costs by increasing capital investment and per-test operational expenses, limiting test menu expansion and slowing the rollout of advanced genetic diagnostics in routine clinical practice. However, they also encourage domestic production of testing reagents and instruments, fostering regional manufacturing capabilities and reducing reliance on imported molecular diagnostics infrastructure over time.

The dna testing market research report is one of a series of new reports that provides dna testing market statistics, including dna testing industry global market size, regional shares, competitors with a dna testing market share, detailed dna testing market segments, market trends and opportunities, and any further data you may need to thrive in the dna testing industry. This dna testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Deoxyribonucleic acid (DNA) testing is the process of analyzing an individual’s DNA, which contains the instructions for an organism’s development, functioning, and traits. It involves extracting DNA from cells, usually obtained from bodily fluids or tissues such as blood, saliva, or hair, and examining specific regions or sequences of the DNA molecule.

The main product types in DNA testing include equipment, consumables, and software and services. Equipment refers to the instruments, devices, and tools used to analyze DNA samples. Various technologies are employed in this testing, including polymerase chain reaction (PCR)-based methods, in-situ hybridization, microarray, and next-generation sequencing (NGS) for DNA analysis. These are applied across multiple areas, such as newborn DNA screening, prenatal DNA carrier screening, oncology diagnostics and histopathology, pre-implantation diagnosis, infectious disease diagnostics, pharmacogenomics testing, identity verification and forensics, and others.

The DNA testing market consists of revenues earned by entities by providing services such as paternity testing, maternity testing, genetic health risk assessment, carrier screening, pharmacogenomics testing, forensic DNA analysis, and nutrigenomics testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The DNA testing market also includes sales of sterile swabs, DNA collection kits, thermal cyclers, DNA sequencers, microarray platforms, DNA extraction kits, polymerase chain reaction (PCR) reagents, and microscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.